South Korean molecular diagnostics firm Seegene has announced the establishment of a new subsidiary in France to reinforce its European presence and support global sales expansion.
France becomes Seegene's eighth overseas sales subsidiary and third in Europe, following Italy and Germany. The new subsidiary will strengthen local engagement with customers and partners through enhanced technical support, market development and collaboration with healthcare stakeholders.
According to global market research firm Grand View Research, France's MDx market is estimated to reach approximately EUR 600 million, accounting for around 15% of Europe's total. It is the second-largest market in the region after Germany (19%). Demand in France is particularly high for diagnostic tests targeting sexually transmitted infections (STIs), gastrointestinal (GI) tract infections, and respiratory infections. Through its subsidiary, Seegene aims to expand sales of these product lines while introducing a broader portfolio including cervical cancer and other multiplex diagnostic categories.
"On the French market, which is divided between the private and public sectors, the ability to quickly deliver innovative products and meet laboratories' efficiency needs is a key factor for competitiveness," said Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene. "The subsidiary will enable Seegene to gain a better understanding the French healthcare landscape, strengthening local customer service, and accelerate the growth of the company's in vitro diagnostics business with dedicated local expertise."
The subsidiary also provides a strategic foothold for the European rollout of Seegene's solutions that are in development, CURECA, a fully automated, unmanned PCR system, and STAgora, a real-time diagnostic data analytics and predictive insights platform.
As of the first half of 2025, overseas sales accounted for approximately 93% of Seegene's total revenue, with Europe representing 63%. The region remains a key growth driver for the company's global expansion roadmap.